Symbols / HOWL Stock $0.52 -5.07% Werewolf Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
HOWL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Daniel J. Hicklin Ph.D.
Exch · Country NMS · United States
Market Cap 25.03M
Enterprise Value -12.60M
Income -56.27M
Sales —
FCF (ttm) -3.69M
Book/sh 0.51
Cash/sh 0.96
Employees 39
Insider 10d —
IPO Apr 30, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.52
PEG —
P/S —
P/B 1.01
P/C —
EV/EBITDA 0.23
EV/Sales —
Quick Ratio 1.21
Current Ratio 1.26
Debt/Eq 72.28
LT Debt/Eq —
EPS (ttm) -1.21
EPS next Y -0.99
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -42.33%
ROE -161.89%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 48.60M
Shs Float 41.23M
Insider Own 5.61%
Instit Own 35.73%
Short Float 1.81%
Short Ratio 2.13
Short Interest 726.86K
52W High 2.38
vs 52W High -78.36%
52W Low 0.50
vs 52W Low 2.61%
Beta —
Impl. Vol. 0.00%
Rel Volume 0.99
Avg Volume 447.34K
Volume 440.88K
Target (mean) $7.00
Tgt Median $7.00
Tgt Low $4.00
Tgt High $10.00
# Analysts 3
Recom None
Prev Close $0.54
Price $0.52
Change -5.07%
About

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.00
Mean price target
2. Current target
$0.52
Latest analyst target
3. DCF / Fair value
$-1.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.52
Low
$4.00
High
$10.00
Mean
$7.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-19 main HC Wainwright & Co. Buy → Buy $4
2025-11-18 main B of A Securities Buy → Buy $7
2025-08-25 main B of A Securities Buy → Buy $8
2025-08-21 main JMP Securities Market Outperform → Market Outperform $3
2025-05-09 main Wedbush Outperform → Outperform $6
2025-03-12 reit Wedbush Outperform → Outperform $8
2025-03-12 reit HC Wainwright & Co. Buy → Buy $15
2025-01-14 main JMP Securities Market Outperform → Market Outperform $4
2024-11-19 reit HC Wainwright & Co. Buy → Buy $15
2024-07-02 reit HC Wainwright & Co. Buy → Buy $15
2024-06-26 reit JMP Securities Market Outperform → Market Outperform $12
2024-06-26 reit HC Wainwright & Co. Buy → Buy $15
2024-06-04 reit JMP Securities Market Outperform → Market Outperform $12
2024-06-03 reit HC Wainwright & Co. Buy → Buy $15
2024-05-24 reit HC Wainwright & Co. Buy → Buy $15
2024-05-06 reit JMP Securities Market Outperform → Market Outperform $12
2024-05-06 reit HC Wainwright & Co. Buy → Buy $15
2024-04-03 init JMP Securities — → Market Outperform $12
2024-03-07 main HC Wainwright & Co. Buy → Buy $15
2023-11-15 reit HC Wainwright & Co. Buy → Buy $15
News
RSS: Latest HOWL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-13 EVNIN LUKE BASIL Director — 44,679 $0.54 $24,127
2026-05-12 EVNIN LUKE BASIL Director — 407,574 $0.64 $280,210
2026-05-12 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 565,167 $0.64 $390,688
2026-05-07 EVNIN LUKE BASIL Director — 100,581 $0.63 $64,217
2026-05-04 EVNIN LUKE BASIL Director — 274,619 $0.72 $198,310
2026-04-29 EVNIN LUKE BASIL Director — 205,911 $0.69 $154,525
2026-01-16 EVNIN LUKE BASIL Director — 38,782 $0.54 $20,942
2026-01-15 EVNIN LUKE BASIL Director — 111,227 $0.55 $61,787
2026-01-12 EVNIN LUKE BASIL Director — 91,374 $0.57 $53,533
2026-01-07 EVNIN LUKE BASIL Director — 71,054 $0.64 $45,882
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
1.89
-90.55%
19.94
+21.60%
16.40
Operating Revenue
0.00
-100.00%
1.89
-90.55%
19.94
+21.60%
16.40
Operating Expense
60.68
-19.61%
75.48
+24.87%
60.45
-16.58%
72.46
Research And Development
44.83
-20.56%
56.43
+35.09%
41.78
-22.29%
53.76
Selling General And Administration
15.85
-16.79%
19.05
+2.01%
18.67
-0.14%
18.70
General And Administrative Expense
15.85
-16.79%
19.05
+2.01%
18.67
-0.14%
18.70
Salaries And Wages
7.36
-23.70%
9.64
+4.99%
9.19
+2.66%
8.95
Other Gand A
7.42
-10.01%
8.25
+7.09%
7.70
+11.72%
6.89
Total Expenses
60.68
-19.61%
75.48
+24.87%
60.45
-16.58%
72.46
Operating Income
-60.68
+17.55%
-73.59
-81.70%
-40.50
+27.75%
-56.06
Total Operating Income As Reported
-60.68
+17.55%
-73.59
-81.70%
-40.50
+27.75%
-56.06
EBITDA
-53.91
+15.82%
-64.05
-97.27%
-32.47
+38.40%
-52.71
Normalized EBITDA
-53.91
+15.09%
-63.49
-95.57%
-32.47
+38.40%
-52.71
Reconciled Depreciation
1.63
-9.92%
1.81
+2.83%
1.76
+59.78%
1.10
EBIT
-55.55
+15.66%
-65.86
-92.41%
-34.23
+36.39%
-53.81
Total Unusual Items
0.00
+100.00%
-0.55
0.00
—
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-0.55
0.00
—
Special Income Charges
0.00
+100.00%
-0.55
0.00
—
Other Special Charges
—
0.55
—
—
Net Income
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Pretax Income
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Net Non Operating Interest Income Expense
-2.17
-207.39%
2.02
-52.84%
4.28
+124.16%
1.91
Interest Expense Non Operating
5.27
+13.27%
4.66
+48.33%
3.14
0.00
Net Interest Income
-2.17
-207.39%
2.02
-52.84%
4.28
+124.16%
1.91
Interest Expense
5.27
+13.27%
4.66
+48.33%
3.14
0.00
Interest Income Non Operating
3.11
-53.42%
6.67
-10.02%
7.42
+288.68%
1.91
Interest Income
3.11
-53.42%
6.67
-10.02%
7.42
+288.68%
1.91
Other Income Expense
2.02
+90.30%
1.06
+192.99%
-1.14
-437.87%
0.34
Other Non Operating Income Expenses
2.02
+25.14%
1.61
+241.42%
-1.14
-437.87%
0.34
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Net Income From Continuing Operation Net Minority Interest
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Net Income From Continuing And Discontinued Operation
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Net Income Continuous Operations
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Normalized Income
-60.82
+13.06%
-69.96
-87.22%
-37.37
+30.56%
-53.81
Net Income Common Stockholders
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
—
-1.63
-55.24%
-1.05
+43.55%
-1.86
Basic EPS
—
-1.63
-55.24%
-1.05
+43.55%
-1.86
Basic Average Shares
—
43.33
+21.56%
35.65
+23.50%
28.86
Diluted Average Shares
—
43.86
+23.04%
35.65
+23.50%
28.86
Diluted NI Availto Com Stockholders
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Insurance And Claims
1.06
-7.47%
1.15
-35.34%
1.78
-37.59%
2.85
Line Item Trend 2023-12-31
Total Assets
174.83
Current Assets
138.37
Cash Cash Equivalents And Short Term Investments
134.34
Cash And Cash Equivalents
134.34
Receivables
1.35
Other Receivables
1.35
Prepaid Assets
—
Other Current Assets
2.68
Total Non Current Assets
36.46
Net PPE
14.85
Gross PPE
18.02
Accumulated Depreciation
-3.17
Properties
0.00
Machinery Furniture Equipment
0.82
Construction In Progress
0.00
Other Properties
9.23
Leases
7.97
Non Current Deferred Assets
—
Other Non Current Assets
21.62
Total Liabilities Net Minority Interest
63.46
Current Liabilities
19.38
Payables And Accrued Expenses
6.57
Payables
1.34
Accounts Payable
1.34
Current Accrued Expenses
5.23
Pensionand Other Post Retirement Benefit Plans Current
3.63
Current Debt And Capital Lease Obligation
8.28
Current Debt
6.67
Other Current Borrowings
6.67
Current Capital Lease Obligation
1.61
Current Deferred Liabilities
0.91
Current Deferred Revenue
0.91
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
44.08
Long Term Debt And Capital Lease Obligation
43.65
Long Term Debt
32.66
Long Term Capital Lease Obligation
10.99
Non Current Deferred Liabilities
0.43
Non Current Deferred Revenue
0.43
Other Non Current Liabilities
—
Stockholders Equity
111.37
Common Stock Equity
111.37
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
39.11
Ordinary Shares Number
39.11
Treasury Shares Number
0.00
Additional Paid In Capital
455.44
Retained Earnings
-344.07
Total Equity Gross Minority Interest
111.37
Total Capitalization
144.03
Working Capital
118.99
Invested Capital
150.70
Total Debt
51.92
Capital Lease Obligations
12.60
Net Tangible Assets
111.37
Tangible Book Value
111.37
Derivative Product Liabilities
0.00
Interest Payable
0.31
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-60.29
-7.30%
-56.19
-72.29%
-32.61
+19.67%
-40.60
Cash Flow From Continuing Operating Activities
-60.29
-7.30%
-56.19
-72.29%
-32.61
+19.67%
-40.60
Net Income From Continuing Operations
-60.82
+13.75%
-70.52
-88.70%
-37.37
+30.56%
-53.81
Depreciation Amortization Depletion
1.63
-9.92%
1.81
+2.83%
1.76
+59.78%
1.10
Depreciation
1.63
-9.92%
1.81
+2.83%
1.76
+59.78%
1.10
Depreciation And Amortization
1.63
-9.92%
1.81
+2.83%
1.76
+59.78%
1.10
Other Non Cash Items
2.93
+31.27%
2.23
+153.87%
0.88
-59.43%
2.16
Stock Based Compensation
6.25
-29.24%
8.83
+10.21%
8.01
+8.22%
7.40
Operating Gains Losses
-2.07
-93.82%
-1.07
—
0.01
Gain Loss On Investment Securities
-2.07
-27.70%
-1.62
—
—
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.01
Change In Working Capital
-8.21
-424.82%
2.53
+142.86%
-5.89
-332.14%
2.54
Change In Receivables
0.00
-100.00%
1.35
-75.80%
5.58
+180.51%
-6.93
Change In Prepaid Assets
0.85
+27.06%
0.67
-47.20%
1.27
+583.59%
-0.26
Change In Payables And Accrued Expense
-7.50
-317.02%
3.46
+179.70%
-4.33
-242.32%
3.05
Change In Accrued Expense
—
—
—
3.74
Change In Payable
-7.50
-317.02%
3.46
+179.70%
-4.33
-242.32%
3.05
Change In Account Payable
-7.50
-317.02%
3.46
+179.70%
-4.33
-242.32%
3.05
Change In Other Working Capital
—
-1.34
+78.80%
-6.32
-194.57%
6.68
Change In Other Current Assets
—
—
—
0.28
Change In Other Current Liabilities
-1.56
+3.17%
-1.61
+22.84%
-2.08
-1191.10%
0.19
Investing Cash Flow
0.00
+100.00%
-0.25
+66.97%
-0.77
+78.70%
-3.61
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.25
+66.97%
-0.77
+78.70%
-3.61
Net PPE Purchase And Sale
0.00
+100.00%
-0.25
+66.97%
-0.77
+78.70%
-3.61
Purchase Of PPE
0.00
+100.00%
-0.25
+66.97%
-0.77
+78.70%
-3.61
Capital Expenditure
—
-0.25
+66.97%
-0.77
+78.70%
-3.61
Financing Cash Flow
6.03
-53.91%
13.08
-77.61%
58.43
+267.34%
15.91
Cash Flow From Continuing Financing Activities
6.03
-53.91%
13.08
-77.61%
58.43
+267.34%
15.91
Net Issuance Payments Of Debt
0.00
+100.00%
-10.00
-125.00%
40.00
0.00
Issuance Of Debt
0.00
-100.00%
30.00
-25.00%
40.00
0.00
Repayment Of Debt
0.00
+100.00%
-40.00
0.00
—
Long Term Debt Issuance
0.00
-100.00%
30.00
-25.00%
40.00
0.00
Long Term Debt Payments
0.00
+100.00%
-40.00
0.00
—
Net Long Term Debt Issuance
0.00
+100.00%
-10.00
-125.00%
40.00
0.00
Net Common Stock Issuance
5.94
-74.81%
23.58
+28.63%
18.33
+16.45%
15.74
Proceeds From Stock Option Exercised
0.09
-49.72%
0.18
+77.00%
0.10
-60.63%
0.25
Net Other Financing Charges
—
-0.67
—
-0.09
Changes In Cash
-54.26
-25.14%
-43.36
-273.12%
25.05
+188.51%
-28.30
Beginning Cash Position
112.22
-27.87%
155.58
+19.19%
130.53
-17.82%
158.83
End Cash Position
57.95
-48.36%
112.22
-27.87%
155.58
+19.19%
130.53
Free Cash Flow
-60.29
-6.82%
-56.44
-69.08%
-33.38
+24.49%
-44.21
Interest Paid Supplemental Data
3.13
-6.70%
3.36
+31.38%
2.56
0.00
Common Stock Issuance
5.94
-74.81%
23.58
+28.63%
18.33
+16.45%
15.74
Issuance Of Capital Stock
5.94
-74.81%
23.58
+28.63%
18.33
+16.45%
15.74
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category